ARGX - חוב כולל להון argenx BVBA

The debt-to-equity ratio for argenx SE (ARGX) provided by the GURU.Markets platform shows a value of 0.01. This trend is supported by sales of the blockbuster Vyvgart and the expansion of its applications. The business relies on an innovative immunological cluster and a protected antibody portfolio. The company's rapid growth is driving the active recruitment of leading scientists, while employee turnover remains minimal.

Investors assess an asset's financial stability through the balance of debt and equity. This metric is calculated as the ratio of total liabilities to equity, measuring the business's degree of reliance on external financing. For argenx SE (ARGX), low leverage is critically important given the high dependence on the commercial success of Vyvgart. Conservative leverage reduces bankruptcy risk in the face of intensifying competition. The current total debt-to-equity ratio confirms the company's margin of safety.